Malignant bone tumors (other than Ewing’s): clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS)

• Published in: Cancer chemotherapy and pharmacology Vol. 80; no. 6; pp. 1113 - 1131
• Main Authors: Redondo, Andrés, Bagué, Silvia, Bernabeu, Daniel, Ortiz-Cruz, Eduardo, Valverde, Claudia, Alvarez, Rosa, Martinez-Trufero, Javier, Lopez-Martin, Jose A., Correa, Raquel, Cruz, Josefina, Lopez-Pousa, Antonio, Santos, Aurelio, García del Muro, Xavier, Martin-Broto, Javier
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.12.2017; Springer Nature B.V
• Subjects: Biocompatibility; Biomedical materials; Biomedical Research; Bone cancer; Bone Neoplasms - diagnosis; Bone Neoplasms - drug therapy; Bone tumors; Cancer Research; Chemotherapy; Chondrosarcoma; Clinical practice guidelines; Decision making; Diagnosis; Follow-Up Studies; Group dynamics; Hispanic or Latino; Historical account; Humans; Medical diagnosis; Medical personnel; Medicine; Medicine & Public Health; Monoclonal antibodies; Motivation; Oncology; Original; Original Article; Osteosarcoma; Pharmacology/Toxicology; Radiation; Radiation therapy; Sarcoma; Sarcoma - diagnosis; Sarcoma - drug therapy; Surgery; Targeted cancer therapy; Tumors; Bone tumors; Treatment; Diagnosis; Clinical guideline; Bone sarcomas
• DOI: 10.1007/s00280-017-3436-0
• ISSN: 0344-5704

Primary malignant bone tumors are uncommon and heterogeneous malignancies. This document is a guideline developed by the Spanish Group for Research on Sarcoma with the participation of different specialists involved in the diagnosis and treatment of bone sarcomas. The aim is to provide practical recommendations with the intention of helping in the clinical decision-making process. The diagnosis and treatment of bone tumors requires a multidisciplinary approach, involving as a minimum pathologists, radiologists, surgeons, and radiation and medical oncologists. Early referral to a specialist center could improve patients’ survival. The multidisciplinary management of osteosarcoma, chondrosarcoma, chordoma, giant cell tumor of bone and other rare bone tumors is reviewed in this guideline. Ewing’s sarcoma will be the focus of a separate guideline because of its specific biological, clinical and therapeutic features. Each statement has been accompanied by the level of evidence and grade of recommendation on the basis of the available data. Surgical excision is the mainstay of treatment of a localized bone tumor, with various techniques available depending on the histologic type, grade and location of the tumor. Chemotherapy plays an important role in some chemosensitive subtypes (such as high-grade osteosarcoma). In other subtypes, historically considered chemoresistant (such as chordoma or giant cell tumor of bone), new targeted therapies have emerged recently, with a very significant efficacy in the case of denosumab. Radiation therapy is usually necessary in the treatment of chordoma and sometimes of other bone tumors.